---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-006158"
form_type: "8-K"
ticker: "COSM"
cik: "0001474167"
company_name: "Cosmos Health Inc."
filed_at: "2026-10-09T21:00:16+00:00"
generated_at: "2026-10-12T15:01:59.168528+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cosmos Health prelim 9-month revenue $54.3M, up 19% YoY; Q3 record $17.4M; FY2026 outlook >$90M reaffirmed

## Summary
- Preliminary nine-month revenue of ~$54.3M, up 19%, or $8.7M, from $45.6M in the first nine months of 2025; figures are unaudited.
- Q3 revenue ~$17.4M vs $17.1M in Q3 2025 (+2%) and $12.4M in Q3 2024 (+40%); Q1, Q2 and Q3 2026 each set a new record for that period.
- Nine-month revenue roughly matches full-year 2024 revenue of $54.4M and equals 83% of record full-year 2025 revenue of $65.3M.
- FY2026 revenue outlook reaffirmed at over $90M (+~38% vs 2025), with Q4 2026 expected to be the strongest quarter in company history.
- Cana Laboratories' contract-manufacturing pipeline hit a record >32.7M units; CosmoFarm distributes to >1,500 pharmacies; Sky Premium Life, C-Scrub and C-Sept brands entered new markets.

## SEC filing metadata
- accession: 0001477932-26-006158
- form_type: 8-K
- ticker: COSM
- cik: 0001474167
- company_name: Cosmos Health Inc.
- filed_at: 2026-10-09T21:00:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1474167/000147793226006158/0001477932-26-006158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1474167/000147793226006158/cosm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-006158
- JSON: https://secwatch.observer/filing/0001477932-26-006158.json
- Plain text: https://secwatch.observer/filing/0001477932-26-006158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.